semaglutide cardiovascular risk The weight-loss drug Wegovy lowered heart attack in a large trial Insights into semaglutide cardiovascular research:

2021;17(S9):e057848

Furthermore, while the majority of clinical trial designs have reasonable endpoints, there are also non-inferiority analyses like SURPASS-AP-Combo.Studies have shown that tirzepatide excels in improving glycemic control and promoting weight loss

If you are taking insulin or sulfonylureas alongside semaglutide, your healthcare provider should adjust those doses downward as you begin GLP-1 therapy, typically reducing them by 2050% initially and monitoring response closely

With semaglutide, some patients report more discomfort or even nausea after consuming them

Sharing pens can spread serious infections, even if the pen looks clean